Literature DB >> 4592597

The effect of insulin on the alpha-cell response to hyperglycemia in long-standing alloxan diabetes.

J T Braaten, G R Faloona, R H Unger.   

Abstract

In acute experimental diabetes in animals, alpha-cell unresponsiveness to hyperglycemia can be promptly corrected by insulin, but in human diabetes, even massive doses of insulin have little effect. To determine if this inability of insulin to correct the alpha-cell abnormality in man is merely the consequence of the long duration of the diabetic state (rather than of a difference in mechanism), the effect of insulin was studied in alloxan diabetes of long duration. Alloxan-diabetic dogs were maintained for 7-18 mo and treated daily with insulin. When glucose was infused without insulin, glucagon did not decline but rose paradoxically. However, when insulin was infused at a rate of 9 mU/kg/min together with glucose, a prompt decline in glucagon from a base-line average of 171 pg/ml SEM+/-34 to a nadir of 41 pg/ml SEM+/-9 was observed. This decline indicated that alpha-cell responsiveness to hyperglycemia is completely restored by large quantities of insulin. To determine if small amounts of insulin would similarly restore alpha-cell responsiveness in long-standing experimental diabetes, 1.4 mU/kg/min was infused. By the time the mean insulin level had risen 43 muU/ml, glucagon had declined significantly and ultimately fell to a nadir of 44 pg/ml. It is concluded from these studies that alpha-cell responsiveness to hyperglycemia can be fully restored in long-standing alloxandiabetic dogs as readily as in acutely diabetic dogs. Its ineffectiveness in restoring alpha-cell responsiveness to hyperglycemia in human diabetes may not, therefore, be related to duration of the diabetic state, and may reflect a primary alpha-cell defect.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4592597      PMCID: PMC333086          DOI: 10.1172/JCI107638

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  8 in total

1.  Measurements of endogenous glucagon in plasma and the influence of blood glucose concentration upon its secretion.

Authors:  R H UNGER; A M EISENTRAUT; M S McCALL; L L MADISON
Journal:  J Clin Invest       Date:  1962-04       Impact factor: 14.808

2.  Immunoassay of endogenous plasma insulin in man.

Authors:  R S YALOW; S A BERSON
Journal:  J Clin Invest       Date:  1960-07       Impact factor: 14.808

3.  Abnormalities of glucagon metabolism in untreated diabetes mellitus.

Authors:  K D Buchanan; A M McCarroll
Journal:  Lancet       Date:  1972-12-30       Impact factor: 79.321

4.  Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion.

Authors:  W A Müller; G R Faloona; E Aguilar-Parada; R H Unger
Journal:  N Engl J Med       Date:  1970-07-16       Impact factor: 91.245

5.  Pancreatic glucagon secretion in normal and diabetic subjects.

Authors:  E Aguilar-Parada; A M Eisentraut; R H Unger
Journal:  Am J Med Sci       Date:  1969-06       Impact factor: 2.378

6.  Coated charcoal immunoassay of insulin.

Authors:  V Herbert; K S Lau; C W Gottlieb; S J Bleicher
Journal:  J Clin Endocrinol Metab       Date:  1965-10       Impact factor: 5.958

7.  The effect of experimental insulin deficiency on glucagon secretion.

Authors:  W A Müller; G R Faloona; R H Unger
Journal:  J Clin Invest       Date:  1971-09       Impact factor: 14.808

8.  Studies of pancreatic alpha cell function in normal and diabetic subjects.

Authors:  R H Unger; E Aguilar-Parada; W A Müller; A M Eisentraut
Journal:  J Clin Invest       Date:  1970-04       Impact factor: 14.808

  8 in total
  26 in total

Review 1.  Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover.

Authors:  Roger H Unger; Alan D Cherrington
Journal:  J Clin Invest       Date:  2012-01-03       Impact factor: 14.808

2.  Identification of glucagon in the gastrointestinal tract.

Authors:  H Sasaki; B Rubalcava; D Baetens; E Blazquez; C B Srikant; L Orci; R H Unger
Journal:  J Clin Invest       Date:  1975-07       Impact factor: 14.808

3.  Decreased glucagon receptors in diabetic rat hepatocytes. Evidence for regulation of glucagon receptors by hyperglucagonemia.

Authors:  S J Bhathena; N R Voyles; S Smith; L Recant
Journal:  J Clin Invest       Date:  1978-06       Impact factor: 14.808

4.  Dissecting the actions of widely used diabetes drugs.

Authors:  Roger H Unger; Eric D Berglund; Joel F Habener; Alan D Cherrington
Journal:  Nat Med       Date:  2013-03       Impact factor: 53.440

5.  Retrograde perfusion as a model for testing the relative effects of glucose versus insulin on the A cell.

Authors:  J I Stagner; E Samols
Journal:  J Clin Invest       Date:  1986-03       Impact factor: 14.808

6.  Hyperglucagonemia precedes a decline in insulin secretion and causes hyperglycemia in chronically glucose-infused rats.

Authors:  Rachel A Jamison; Romana Stark; Jianying Dong; Shin Yonemitsu; Dongyan Zhang; Gerald I Shulman; Richard G Kibbey
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-08-23       Impact factor: 4.310

7.  Glucagon gene transcription is negatively regulated by insulin in a hamster islet cell line.

Authors:  J Philippe
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

8.  Comparison of the suppressive effects of elevated plasma glucose and free fatty acid levels on glucagon secretion in normal and insulin-dependent diabetic subjects. Evidence for selective alpha-cell insensitivity to glucose in diabetes mellitus.

Authors:  J E Gerich; M Langlois; C Noacco; M Lorenzi; J H Karam; P H Korsham
Journal:  J Clin Invest       Date:  1976-08       Impact factor: 14.808

9.  Insulin and the glucose-glucagon feedback mechanism in the duck.

Authors:  F Laurent; P Mialhe
Journal:  Diabetologia       Date:  1976-03       Impact factor: 10.122

Review 10.  Glucagon physiology and pathophysiology in the light of new advances.

Authors:  R H Unger
Journal:  Diabetologia       Date:  1985-08       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.